Fumetinib mesylate is now recruiting at multiple centers across the country for lung cancer with EGFR exon 20 insertion mutations
There are currently three third-generation EGFR lung cancer targeting drugs that have been approved for marketing in China: osimertinib, ametinib, and fumetinib, the latter two of which are domestically produced drugs.
Eversar® (vometinib mesylate) is a third-generation EGFR-TKI originally developed in China with independent intellectual property rights . It has the characteristics of “dual activity, high selectivity, strong tumor shrinkage, and good safety.”
Indications:
1. First-line treatment for advanced non-small cell lung cancer with EGFR gene exon 19 deletion mutation or L858R point mutation;
2. Second-line treatment for advanced non-small cell lung cancer with T790M mutation after resistance to targeted drugs.
3. At the same time, as a third-generation EGFR inhibitor, the efficacy of fumetinib in treating ex20ins patients is much higher than the existing data of osimertinib (according to the current data published by both parties), and the potential is worth exploring.
Since fumetinib itself was launched late, it is difficult to catch up with the pioneers using the same strategy. Therefore, the development direction of indications has turned to a rare mutation that is urgently needed in clinical practice and has no marketed drug in China – EGFR exon 20 insertion. . The clinical evidence included as a breakthrough therapy this time comes from the Phase 1B clinical trial (CTR20201697) registered by Ellis in August 2020, which was led by Director Han Baohui of Shanghai Chest Hospital. Being able to enter the Breakthrough Therapy List with such early clinical results is enough to demonstrate the outstanding efficacy of fumetinib in the treatment of EGFR exon 20 insertion NSCLC.
According to the trial results announced at the ESMO conference, after using fumetinib in 10 patients with EGFR ex20ins, 7 of them have achieved clinical partial response, which means that the current clinical response rate is 70%!
The reduction of target lesions was observed in all 10 patients, ranging from 3% to 72.3%, and the current disease control rate is as high as 100%!
